Lonza seeks drug industry veteran as CEO to sharpen pharma focus
Net profit last year was 646 million francs versus 563 million in 2018, the Basel-based company said. Sales rose 6.8 per cent to…
Author
Acasti Pharma’s krill oil-derived drug fails late-stage study
The Canada-based drug developer said CaPre failed to show a statistically significant reduction in blood triglycerides compared to…
Biogen to buy early-stage potential Alzheimer’s, Parkinson’s treatment from Pfizer
Under the deal, Pfizer will get $75 million upfront and will be eligible for $635 million in potential milestone payments
Switzerland’s Obseva eyes China re-start for fertility drug that failed trial
In November last year, ObsEva said it was scrapping a development programme for nolasiban to help women undergoing in-vitro…
AstraZeneca to discontinue Epanova trial, expects $100 mn writedown
The drug is already approved in the United States to reduce high levels of triglyceride in adult patients
Drug developers take fresh aim at ‘guided-missile’ cancer drugs
These antibody-drug conjugates, or ADCs, from companies including AztraZeneca and GlaxoSmithKline, are described by researchers as…
Novartis, Merck and Allergan join those raising US drug prices for 2020
Novartis, Merck and Allergan Plc were among companies that raised US prices on more than 100 prescription medicines on Friday,…
Drugmakers from Pfizer to GSK to hike US prices on over 200 drugs
More price increases are expected to be announced later this week, which could affect the median and range
US FDA declines to approve GSK drugs division’s long acting HIV injection
ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in…
US antitrust enforcers give Roche approval to buy Spark Therapeutics
The FTC approved the deal, which was originally announced in February, without requiring any asset sales to ensure that the…